CEHRA Profile
CEHRA

@CEHRAhus

Followers
37
Following
27
Media
0
Statuses
41

Centre of Hematological Research at Ahus, Norway. We do clinical studies on venous thrombosis and on precision medicine in MDS/AML in the elderly.

Lørenskog, Norway
Joined November 2021
Don't wanna be here? Send us removal request.
@mmonrealriete
manuel monreal
2 years
And because the 30-day mortality after recurrent VTE was unexpectedly low The #RIETEregistry experience externally validated using the #COMMAND-VTE registry data
@mmonrealriete
manuel monreal
2 years
That’s because even in the absence of anticoagulation, some patients bled We provide info on how to identify them The #RIETEregistry experience
0
3
3
@MarcCarrier1
Marc Carrier
2 years
From veins to brains: Shifting paradigm in Cancer Associated Thrombosis. Strokes are common just before or right after cancer diagnosis. Cancer types, prior history of stroke and tumor stage are important predictors of CVA. More studies are needed. #ICTHIC2024
1
21
57
@BloodPortfolio
Blood Journals Portfolio
2 years
How I treat multiple myeloma in geriatric patients https://t.co/EIpnNva88Z #geriatrichematology #lymphoidneoplasia #multiplemyeloma
0
40
111
@Haematologica
Haematologica
2 years
The crazy case of a #T-cell ALL that switched to acute myeloid leukemia shortly after #CART-cellTherapy targeting #CD7. #Myeloid switch could be a new escape mechanism of leukemia under the pressure of targeting CD7. https://t.co/99fQeqnofR
4
59
165
@CEHRAhus
CEHRA
2 years
One step forward in precision knowledge in AML. Unfit NPM1 mutated AML had shorter survival when ATRA was added to LDAC + etoposide.
0
0
0
@BloodAdvances
Blood Advances
2 years
FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years https://t.co/3zcgMdMacU #researchletter #clinicaltrialsandobservations #myeloidneoplasia
4
12
37
@DrHKantarjian
Hagop Kantarjian,MD
2 years
Treatment of FLT3-mutated #AML in older pts remains a challenge. New HMA + venetoclax + FLT3 inhibitor triplet regimens may improve outcomes. @NicholasShortMD of @MDAndersonNews #Leukemia https://t.co/G2cDKnoExn @BloodCancerJnl #leusm
1
37
129
@TheLancetHaem
The Lancet Haematology
2 years
"The existence of two acute myeloid leukaemia classification systems...is concerning... and threatens the ability to... deliver appropriate... management strategies" ICYMI Viewpoint—Standardising acute myeloid leukaemia classification systems #leusm https://t.co/LD5Qww3g34
0
55
151
@TriLarsen
Trine-Lise Larsen
2 years
https://t.co/zFB1asNWaZ Read our preprint of arterial thrombosis in cancer patients from The CAP study. Here we analyze arterial thrombosis as serious adverse events in patient with venous thrombosis treated with apixaban.
0
3
3
@isth
ISTH
3 years
Why should you come to #ISTH2023? Listen to these attendees to find out, including @HanineELItawi, @Sps_dhami, @GuyYoungMD, @Sean_Patmore and @Cihan_Ay_MD. Be sure to register before the early deadline on April 20 for discounted rates!
1
3
16
@MarcCarrier1
Marc Carrier
3 years
Recent studies have been reporting low rates of symptomatic VTE beyond discharge following colorectal and ovarian cancer surgery. Should every patients still receive extended prophylaxis? High-risk only? @hagridsbeard92 at @KFSHRC, @TzufeiWang @JTHjournal https://t.co/c6UeeMoboq
1
17
40
@ProfMakris
Michael Makris
3 years
Monoclonal Gammopathy of Thrombotic/Thrombocytopenic Significance will be a new term for most of us. Paper in press in @BloodJournal. If you have a patient with a monoclone, thrombosis and thrombocytopenia, test them for anti-PF4 using an ELISA assay. https://t.co/aRB6s7aQqj
5
90
277
@GBarnesMD
Geoff Barnes
3 years
.@bhwords reminds us about the limitations of “thrombophilia testing.” Did you know that 95% of people with heterozygous Factor V Leiden will never develop #VTE? Be very selective in whom (and when) you test. #PERT2022
3
17
65
@CEHRAhus
CEHRA
3 years
Two of our students studied diagnostic accuracy of spinal fractures in multiple myeloma patients. They found surprisingly low inter-observer agreement. And both CT and MRI over-diagnosed spinal fractures. https://t.co/AWeTRdEmcn.
mdpi.com
Skeletal disease is common in multiple myeloma.
0
0
0
@CEHRAhus
CEHRA
3 years
2022 ESC Guidelines on cardio-oncology. Impressive work. Something to learn for all who treats cancer patients.
0
0
0
@ProfMakris
Michael Makris
3 years
Large US study found an increase in venous thromboembolism in patients hospitalised with #COVID19 in comparison to those hospitalised with influenza. No statistical difference for arterial thrombosis. https://t.co/RYQb2FzusL #thrombosis
2
11
26
@JournalCancer
ACS Journal Cancer
3 years
This review provides detailed insight on the novel drugs currently in use and those being explored in the management of blastic plasmacytoid dendritic cell neoplasm (#BPDCN), a rare hematologic malignancy arising from precursor dendritic cells https://t.co/K7K9SMwqqE @doctorpemm
0
3
8
@canvector
CanVECTOR Network
4 years
Let's #DiscussCLOTPlus: American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of #Anticoagulants and Antiplatelets During Acute Gastrointestinal #Bleeding and the Periendoscopic Period https://t.co/Qv8YYZPKP7
0
3
3
@Mohty_EBMT
Mohamad Mohty
4 years
Just published in ⁦@BloodCancerJnl⁩ open access. ⁦@Florent_Malard⁩ ⁦@abazarbachi⁩ ⁦@VincentRK⁩ ⁦@szusmani⁩ ⁦@End_myeloma⁩ ⁦@Transplant_Doc⁩ ⁦@MyelomaTeacher⁩ ⁦@myelomaMD⁩ ⁦@mvmateos⁩ ⁦@MM_Hub
1
28
91